Advanced search
1 file | 2.33 MB Add to list

Exploring prime-boost vaccination regimens with different H1N1 swine influenza a virus strains and vaccine platforms

(2022) VACCINES. 10(11).
Author
Organization
Abstract
In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination. However, no pan-H1 antibody response was induced. Therefore, to stimulate both local and systemic immune responses, we first vaccinated pigs intranasally with a pseudorabies vector vaccine expressing the pH1N1 hemagglutinin (prvCA09) followed by a homologous or heterologous WIV booster vaccine. Homologous and heterologous WIV-WIV vaccinated groups and mock-vaccinated or prvCA09 single-vaccinated pigs served as control groups. Five weeks after the second vaccination, pigs were challenged with a homologous pH1N1 or one of two heterologous H1N2 swine influenza A virus strains. A single prvCA09 vaccination resulted in complete protection against homologous challenge, and vector-WIV vaccinated groups were significantly better protected against heterologous challenge compared to the challenge control group or WIV-WIV vaccinated groups. Furthermore, vector-WIV vaccination resulted in broader hemagglutination inhibition antibody responses compared to WIV-WIV vaccination and higher numbers of antibody-secreting cells in peripheral blood, draining lymph nodes and nasal mucosa. However, even though vector-WIV vaccination induced stronger antibody responses and protection, we still failed to induce a pan-H1 antibody response.
Keywords
swine influenza A virus, H1N1, vaccination, heterologous prime-boost, vectored vaccine, attenuated PrV strain Bartha, antibody, cross-reactivity, ELISPOT, cross-protection, PSEUDORABIES VIRUS, IMMUNE-RESPONSES, PIGS, HEMAGGLUTININ, EFFICACY, PROTECTION, INFECTION, OUTBREAK, VECTOR, FARM

Downloads

  • vaccines-10-01826.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 2.33 MB

Citation

Please use this url to cite or link to this publication:

MLA
Parys, Anna, et al. “Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza a Virus Strains and Vaccine Platforms.” VACCINES, vol. 10, no. 11, 2022, doi:10.3390/vaccines10111826.
APA
Parys, A., Vandoorn, E., Chiers, K., Passvogel, K., Fuchs, W., Mettenleiter, T. C., & Van Reeth, K. (2022). Exploring prime-boost vaccination regimens with different H1N1 swine influenza a virus strains and vaccine platforms. VACCINES, 10(11). https://doi.org/10.3390/vaccines10111826
Chicago author-date
Parys, Anna, Elien Vandoorn, Koen Chiers, Katharina Passvogel, Walter Fuchs, Thomas C. Mettenleiter, and Kristien Van Reeth. 2022. “Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza a Virus Strains and Vaccine Platforms.” VACCINES 10 (11). https://doi.org/10.3390/vaccines10111826.
Chicago author-date (all authors)
Parys, Anna, Elien Vandoorn, Koen Chiers, Katharina Passvogel, Walter Fuchs, Thomas C. Mettenleiter, and Kristien Van Reeth. 2022. “Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza a Virus Strains and Vaccine Platforms.” VACCINES 10 (11). doi:10.3390/vaccines10111826.
Vancouver
1.
Parys A, Vandoorn E, Chiers K, Passvogel K, Fuchs W, Mettenleiter TC, et al. Exploring prime-boost vaccination regimens with different H1N1 swine influenza a virus strains and vaccine platforms. VACCINES. 2022;10(11).
IEEE
[1]
A. Parys et al., “Exploring prime-boost vaccination regimens with different H1N1 swine influenza a virus strains and vaccine platforms,” VACCINES, vol. 10, no. 11, 2022.
@article{01GQJ7XNKYT3NSTX8JNF81TS28,
  abstract     = {{In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination. However, no pan-H1 antibody response was induced. Therefore, to stimulate both local and systemic immune responses, we first vaccinated pigs intranasally with a pseudorabies vector vaccine expressing the pH1N1 hemagglutinin (prvCA09) followed by a homologous or heterologous WIV booster vaccine. Homologous and heterologous WIV-WIV vaccinated groups and mock-vaccinated or prvCA09 single-vaccinated pigs served as control groups. Five weeks after the second vaccination, pigs were challenged with a homologous pH1N1 or one of two heterologous H1N2 swine influenza A virus strains. A single prvCA09 vaccination resulted in complete protection against homologous challenge, and vector-WIV vaccinated groups were significantly better protected against heterologous challenge compared to the challenge control group or WIV-WIV vaccinated groups. Furthermore, vector-WIV vaccination resulted in broader hemagglutination inhibition antibody responses compared to WIV-WIV vaccination and higher numbers of antibody-secreting cells in peripheral blood, draining lymph nodes and nasal mucosa. However, even though vector-WIV vaccination induced stronger antibody responses and protection, we still failed to induce a pan-H1 antibody response.}},
  articleno    = {{1826}},
  author       = {{Parys, Anna and Vandoorn, Elien and Chiers, Koen and  Passvogel, Katharina and  Fuchs, Walter and  Mettenleiter, Thomas C. and Van Reeth, Kristien}},
  issn         = {{2076-393X}},
  journal      = {{VACCINES}},
  keywords     = {{swine influenza A virus,H1N1,vaccination,heterologous prime-boost,vectored vaccine,attenuated PrV strain Bartha,antibody,cross-reactivity,ELISPOT,cross-protection,PSEUDORABIES VIRUS,IMMUNE-RESPONSES,PIGS,HEMAGGLUTININ,EFFICACY,PROTECTION,INFECTION,OUTBREAK,VECTOR,FARM}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{16}},
  title        = {{Exploring prime-boost vaccination regimens with different H1N1 swine influenza a virus strains and vaccine platforms}},
  url          = {{http://doi.org/10.3390/vaccines10111826}},
  volume       = {{10}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: